NOTCH1 and acute lymphoblastic leukemia: Importantly, thapsigargin preferentially targets mutated NOTCH1 proteins, as shown by its antileukemic effect and the lack of gastrointestinal toxicity in a human T-ALL xenograft murine model treated with 0.4 mg/kg thapsigargin, in sharp contrast with previous experiences with GSI [176].